Document:

Exhibit 10.2 CelgeneThirdAmendmentFinalRedacted

EXHIBIT 10.2

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

THIRD AMENDMENT TO DRUG DISCOVERY AND DEVELOPMENT AGREEMENT

THIS THIRD AMENDMENT TO DRUG DISCOVERY AND DEVELOPMENT AGREEMENT (“Amendment”), effective as of November 29, 2012 (the “Amendment Date”), is entered into by and between Celgene Corporation, a Delaware corporation, having a principal place of business 86 Morris Avenue, Summit, NJ 07901 (“Celgene”), and Array BioPharma Inc., a Delaware corporation, having a principal place of business at 3200 Walnut Street, Boulder, Colorado 80301 (“Array”).  Celgene and Array are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”  Capitalized terms used but not defined herein have the meaning assigned to them in the Agreement (as defined below).
WHEREAS, Celgene and Array entered into that certain Drug Discovery and Development Agreement, effective as of September 21, 2007, as amended on June 17, 2009 and on January 8, 2012 (collectively, the “Agreement”);
WHEREAS, pursuant to Section 3.5 of the Agreement, the Joint Research Committee [ * ];
WHEREAS, based on the results of the further studies on such [ * ], the Parties agreed that such [ * ] would not be [ * ], thereby ending Array’s obligation to conduct the Discovery Program with respect to the Target [ * ], but not ending the Option Term for [ * ];
WHEREAS, the Parties desire to continue the Discovery Program with respect to the Target [ * ], and, based on the results of the continued Discovery Program, the JRC has, in accordance with Section 3.5.1 of the Agreement, determined that certain Compound(s) that [ * ] are available for selection as Lead Compound(s) for advancement into [ * ];
WHEREAS, the Parties desire to conduct [ * ] for such potential Lead Compound(s), advance certain of such additional modulators into [ * ], as further described at Exhibit A; and
WHEREAS, the Parties desire to amend the Agreement as set forth below.
NOW, THEREFORE, in consideration of the promises and mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:
		
	1.
	This Amendment hereby amends and revises the Agreement to incorporate the terms and conditions set forth in this Amendment.  The relationship of the Parties shall continue to be governed by the terms of the Agreement, as amended.

		
	2.
	In partial consideration of this Amendment, Celgene will pay to Array Three Million Dollars (U.S. $3,000,000) within fifteen (15) days following the Amendment Date to fund the [ * ] Work Plan as set forth at Exhibit A. 

1 of 3

EXHIBIT 10.2

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

		
	3.
	Selection of Development Compounds and Development Back-Up Compounds, if any, shall be in accordance with the terms of the Agreement, including Sections 3.5.2 and 3.5.3.

		
	4.
	If, within [ * ] the selection of such Development Compounds and Development Back-Up Compounds, Celgene exercises the Celgene Product Option with respect to any Development Compound and any corresponding Back-Up Compounds directed to [ * ], then, in consideration of Celgene’s [ * ] of such Celgene Product Option, the [ * ] Discovery Milestone for the [ * ] Target, as set forth at Section 6.2, shall be reduced to [ * ]. If Celgene does not exercise such Celgene Product Option within such [ * ], the Discovery Milestone shall not be reduced.

		
	5.
	For purposes of clarity, the Option Term for the Target [ * ] remains in full force and effect and shall continue in accordance with Section 4.1 of the Agreement (i.e., commencing on the Effective Date).

IN WITNESS WHEREOF, Celgene and Array have caused this Third Amendment to Drug Discovery and Development Agreement to be executed by their respective duly authorized representatives as of the date and year first written above.

	
		
	CELGENE CORPORATION

	ARRAY BIOPHARMA INC.

	By:    /s/ Perry Karsen         

	By:   /s/  John R. Moore         

	Name:     Perry Karsen            

	Name:     John Moore            

	Title:     EVP, COO            

	Title:    General Counsel         

2 of 3

EXHIBIT 10.2

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

Attachment A

[ * ] Work Plan

Please see attached.

[ * ]

3 of 3Exhibit 10.3 Comerica-ArrayBioPharma-EighthAmendmenttoLoanandSecurityAgreement122012FiledVersion

EXHIBIT 10.3

EIGHTH AMENDMENT TO LOAN AND SECURITY AGREEMENT
This Eighth Amendment to Loan and Security Agreement (this “Amendment”) is entered into as of December 28, 2012, by and between COMERICA BANK (“Bank”) and ARRAY BIOPHARMA, INC. (“Borrower”).
RECITALS
Borrower and Bank are parties to that certain Loan and Security Agreement dated as of June 28, 2005, as amended from time to time, including by that certain First Amendment to Loan and Security Agreement dated as of December 19, 2005, that certain Second Amendment to Loan and Security Agreement, Consent and Waiver dated as of July 7, 2006, that certain Third Amendment to Loan and Security Agreement dated as of June 12, 2008, that certain Fourth Amendment to Loan and Security Agreement dated as of March 11, 2009, that certain Fifth Amendment to Loan and Security Agreement dated as of September 30, 2009, that certain Sixth Amendment to Loan and Security Agreement dated as of March 31, 2010, that certain bilateral extension letter dated as of March 4, 2011 and that certain Seventh Amendment to Loan and Security Agreement dated as of June 11, 2011 (collectively, the “Agreement”).  The parties desire to amend the Agreement in accordance with the terms of this Amendment.
NOW, THEREFORE, the parties agree as follows:
1.The following defined term in Section 1.1 of the Agreement hereby is amended and restated as follows:
 “Refinance Term Loan Maturity Date” means October 26, 2014.

“Revolving Maturity Date” means June 9, 2014. 

2.    No course of dealing on the part of Bank or its officers, nor any failure or delay in the exercise of any right by Bank, shall operate as a waiver thereof, and any single or partial exercise of any such right shall not preclude any later exercise of any such right.  Bank’s failure at any time to require strict performance by Borrower of any provision shall not affect any right of Bank thereafter to demand strict compliance and performance.  Any suspension or waiver of a right must be in writing signed by an officer of Bank.
3.    Unless otherwise defined, all initially capitalized terms in this Amendment shall be as defined in the Agreement.  The Agreement, as amended hereby, shall be and remain in full force and effect in accordance with its respective terms and hereby is ratified and confirmed in all respects.  Except as expressly set forth herein, the execution, delivery, and performance of this Amendment shall not operate as a waiver of, or as an amendment of, any right, power, or remedy of Bank under the Agreement, as in effect prior to the date hereof.
4.    Borrower represents and warrants that the Representations and Warranties contained in the Agreement are true and correct as of the date of this Amendment, and that no Event of Default has occurred and is continuing.  
5.    As a condition to the effectiveness of this Amendment, Bank shall have received, in form and substance satisfactory to Bank, the following:
(a)    this Amendment, duly executed by Borrower;
(b)    an Affirmation of Amended and Restated Subordination Agreement executed by each holder of Subordinated Debt;
(c)    all reasonable Bank Expenses incurred through the date of this Amendment, which may be debited from any of Borrower's accounts; and

WEST\239578039.2 
329034-000390    -1-

(d)    such other documents, and completion of such other matters, as Bank may reasonably deem necessary or appropriate.
6.    This Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one instrument.

 

[Balance of Page Intentionally Left Blank]

- 2 -
WEST\239578039.2 
329034-000390 

IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the first date above written.
	
		
	 
	ARRAY BIOPHARMA, INC.

	 
	 

	 
	 

	 
	By:  /s/ R. Michael Carruthers   

	 
	 

	 
	Title:  Chief Financial Officer   

	 
	 

	 
	COMERICA BANK

	 
	 

	 
	 

	 
	By:  /s/ Michael Fishback   

	 
	 

	 
	Title:  Vice President   

[Signature Page to Eighth Amendment to Loan and Security Agreement]

WEST\239578039.2 
329034-000390Exhibit 10.4 Array-AmendmenttoDeerfieldFacilityAgreementsFiledCopy

EXHIBIT 10.4

AMENDMENT TO FACILITY AGREEMENTS

This Amendment to Facility Agreements (this “Amendment”) is hereby entered into as of December 28, 2012 by and between Array BioPharma Inc. (“Array”) and Deerfield Private Design Fund, L.P. and Deerfield Private Design International, L.P. (“Deerfield”).

Array and Deerfield desire to amend that certain Facility Agreement dated May 15, 2009 (the “2009 Facility Agreement”) entered into by and between Array and Deerfield and that certain Facility Agreement dated April 29, 2008 (the “2008 Facility Agreement”) entered into by and between Borrower and Deerfield as provided herein.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

1.Section 5.2(d) of the 2009 Facility Agreement and Section 5.2(d) of the 2008 Facility Agreement are each hereby amended and replaced in their entirety with the following:
(d)    The Borrower shall not amend or grant any waiver of any term or condition of the Senior Debt or the documents evidencing the Senior Debt; provided, however, that the Borrower may not (i) extend the Comerica Loan Agreement beyond October 26, 2014 or (ii) increase the aggregate amount of the Credit Extensions (as such term is defined therein) in excess of a maximum aggregate principal amount of $15,000,000.
2.    Except as expressly modified herein, the 2009 Facility Agreement and the 2008 Facility Agreement shall be unmodified and remain in full force and effect.
3.    This Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which shall constitute one instrument.
[Signature pages follow.]

IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the first date above written.

ARRAY BIOPHARMA INC.

By:     /s/ R. Michael Carruthers     
       R. Michael Carruthers
       Chief Financial Officer

DEERFIELD PRIVATE DESIGN FUND, L.P.
By:  /s/ James E. Flynn    
      Name: James E. Flynn
      Title: President 

DEERFIELD PRIVATE DESIGN INTERNATIONAL, L.P.
By:  /s/ James E. Flynn    
      Name: James E. Flynn
      Title: President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00212-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00212-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00212-of-00352.parquet"}]]